Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Dose Dense MVAC in Muscle Invasive Bladder Cancer
NCT01031420Phase 2Completed
- Sponsor
- Fox Chase Cancer Center
- Start
- Dec 2009
- Primary completion
- Jul 2013
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methotrexate, vinblastine, doxorubicin and cisplatin in bladder cancer and upper tract urothelial carcinoma (UTUC), sponsored by Fox Chase Cancer Center. Primary endpoint: Percentage of Participants With Complete Response at Cystectomy or Ureterectomy at 9 weeks. Started Dec 2009; status: completed.
02
Drugs
methotrexatevinblastinedoxorubicincisplatin
03
Conditions
bladder cancerupper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on NCT01031420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01031420.